Grand River Aseptic Manufacturing (GRAM), a provider of parenteral solutions, is now under majority ownership of Arlington Capital Partners, a private equity firm in the Washington, D.C., area. The new partnership will enable GRAM to meet the growing development and commercial demand in many sectors of the injectables market, including biologics and generics.

GRAM’s facilities support pharmaceutical development, cGMP manufacturing, analytical testing, and regulatory filing. They were recently named one of the country’s fastest growing private companies, according to INC. 5000, and is Michigan’s ninth fastest growing private company. 

“The additional capital and industry knowledge that Arlington provides will aid in sustaining the historical growth rates,” said Tom Ross, chief executive officer of GRAM. “Since we opened our doors in January 2011, the employee count has grown from 16 to over 160 today.”